Anika Q2 revenue rises 16% to $32.6 million; raises 2026 guidance
Anika Therapeutics reported second-quarter 2026 revenue of $32.6 million, up 16% from a year earlier, and net income of $3.3 million, compared with a net loss of $4.0 million in the prior-year quarter. The company raised its 2026 revenue and adjusted EBITDA margin guidance, but cut its 2027 Commercial Channel revenue forecast and removed Hyalofast revenue from that forecast pending FDA approval.
Key points
- Q2 2026 revenue was $32.6 million, up from $28.2 million in Q2 2025; Commercial Channel revenue was a record $13.9 million.
- Q2 2026 net income was $3.3 million, or $0.24 per diluted share, versus a net loss of $4.0 million a year earlier.
- 2026 revenue growth guidance raised to 5% to 10% from 1% to 9%; adjusted EBITDA margin guidance raised to 13% to 17% from 5% to 10%.
- 2027 Commercial Channel revenue growth guidance lowered to 5% to 15% from 10% to 20%, excluding Hyalofast, which is still under FDA review.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.